{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:54Z","timestamp":1781835174629,"version":"3.54.5"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/jac\/dkx360","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T17:56:57Z","timestamp":1504720617000},"page":"126-133","source":"Crossref","is-referenced-by-count":32,"title":["Potential of high-dose cefepime\/tazobactam against multiresistant Gram-negative pathogens"],"prefix":"10.1093","volume":"73","author":[{"given":"David M","family":"Livermore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazad","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Woodford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,20]]},"reference":[{"key":"key\n\t\t\t\t20171215014135_dkx360-B1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/31.suppl_A.9","article-title":"Determinants of the activity of \u03b2-lactamase inhibitor combinations","volume":"31","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B3","doi-asserted-by":"crossref","first-page":"20140086.","DOI":"10.1098\/rstb.2014.0086","article-title":"Time for a change: addressing R&D and commercialization challenges for antibacterials","volume":"370","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1469-0691.2007.01858.x","article-title":"Orthodox and unorthodox clavulanate combinations against extended-spectrum \u03b2-lactamase producers","volume":"14","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B5","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory","volume":"39","year":"2001","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B6","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B7","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-sixth Informational Supplement M100-S26","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10096-011-1183-4","article-title":"In vitro activity of \u03b2-lactam antibiotics against CTX-M-producing Escherichia coli","volume":"30","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B9","first-page":"165","article-title":"CTX-M: changing the face of ESBLs in Europe","volume":"59","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B10"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B11","author":"Medline India"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5799\/ahinjs.02.2012.03.0049","article-title":"Clinical profile of patients treated with cefepime\/tazobactam: a new \u03b2-lactam\/\u03b2-lactamase inhibitor combination","volume":"2","year":"2012","journal-title":"J Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B13","first-page":"HC05","article-title":"Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection\u2014a prospective comparative study","volume":"8","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.idc.2016.02.007","article-title":"New \u03b2-lactamase inhibitors in the clinic","volume":"30","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B16","first-page":"2278","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","year":"2107","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B17","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically\u2014Ninth Edition: Approved Standard M7-A9","author":"Clinical and Laboratory Standards Institute","year":"2011"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/AAC.48.1.15-22.2004","article-title":"Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae","volume":"48","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B19","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","article-title":"Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus \u03b2-lactamase-producing Enterobacteriaceae","volume":"65","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B20","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1128\/AAC.00656-13","article-title":"Pharmacological basis of \u03b2-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B21","article-title":"Pharmacokinetics-pharmacodynamics of tazobactam in combination with cefepime in an in vitro infection model","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/29.suppl_A.1","article-title":"Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation cephalosporins","volume":"29","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B23","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/AAC.00029-07","article-title":"Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae","volume":"51","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jac\/dkg114","article-title":"Variable susceptibility to piperacillin\/tazobactam amongst Klebsiella spp. with extended-spectrum \u03b2-lactamases","volume":"51","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B25","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1128\/AAC.39.8.1856","article-title":"Effect of pH on activities of novel \u03b2-lactamases and \u03b2-lactamase inhibitors against these \u03b2-lactamases","volume":"39","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","article-title":"In vitro activity of avibactam (NXL104) in combination with \u03b2-lactams against Gram-negative bacteria, including OXA-48 \u03b2-lactamase-producing Klebsiella pneumoniae","volume":"39","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1128\/AAC.00693-09","article-title":"Inhibitor resistance in the KPC-2 \u03b2-lactamase, a preeminent property of this class A \u03b2-lactamase","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171215014135_dkx360-B28","first-page":"e02409","article-title":"Antimicrobial activity of high-proportion cefepime\/tazobactam (WCK 4282) against a large number of Gram-negative isolates collected worldwide in 2014","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/1\/126\/22755717\/dkx360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T02:51:32Z","timestamp":1513306292000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/73\/1\/126\/4558669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,10,20]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx360","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2017,10,20]]}}}